What hemodynamic profile defines cardiogenic shock and which initial pharmacologic strategies are used?

• A. Normal CO with high SVR; use phenylephrine
• B. High cardiac output with low filling pressures; use nitroprusside and milrinone
• C. Low cardiac output with elevated left-sided filling pressures (high PCWP) and hypotension; initial management includes norepinephrine as a vasopressor and dobutamine as an inotrope, with definitive MI treatment.
• D. Low CO with low PCWP; use dopamine

Answer: (C)

In cardiogenic shock the heart is not pumping effectively, so cardiac output falls and tissue perfusion decreases. The failure is primarily left-sided, so pressures backing up into the left heart rise, producing an elevated left-sided filling pressure (high PCWP). The patient becomes hypotensive because forward flow is inadequate. The goal of initial therapy is to stabilize perfusion by increasing both pressure and flow. Norepinephrine is used as a vasopressor to raise mean arterial pressure and improve coronary and systemic perfusion without overly dilating the vessels, which can worsen perfusion in a failing heart. Dobutamine is added to boost contractility and stroke volume, which raises cardiac output and helps reduce LV filling pressures as perfusion improves. In the context of an acute myocardial infarction, definitive treatment is rapid reperfusion to restore blood flow to the affected myocardium. Other approaches that focus mainly on reducing afterload or that rely on beta-agonists alone can worsen symptoms if blood pressure is already low, so the combination of norepinephrine with dobutamine best fits the typical hemodynamic profile and initial management.